RESUMO
Background Fatty acid ß-oxidation disorders (FAODs) include more than 15 distinct disorders and have a wide variety of symptoms, usually not evident between episodes of acute decompensation. After the introduction of newborn screening (NBS) using tandem mass spectrometry (MS/MS), early identification of FAODs has become feasible. We analyzed the MS/MS results in Tianjin, China during a six-year period to evaluate the incidence, disease spectrum, and genetic characteristics of FAODs. Methods We analyzed the MS/MS results for screening FAODs from May 2013 to December 2018 in Tianjin, China. Infants with positive screening results were confirmed through next-generation sequencing and validated by Sanger sequencing. Results A total of 220,443 infants were screened and 25 FAODs patients were identified (1:8,817). Primary carnitine deficiency (PCD) with an incidence rate up to 1:20,040 was the most common disorder among all FAODs. Recurrent mutations of relatively common diseases, like PCD and short-chain acyl-CoA dehydrogenase deficiency (SCADD), were identified. During the follow-up, two patients suffered from sudden death due to carnitine palmitoyl transferase-â ¡ deficiency (CPT â ¡) and very-long-chain acyl-CoA dehydrogenase deficiency (VLCAD). Conclusion Our data indicated that FAODs are relatively common in Tianjin and may even cause infant death in certain cases. The elucidated disease spectrum and genetic backgrounds elucidated in this study may contribute to the treatment and prenatal genetic counseling of FAODs.
Assuntos
Ácidos Graxos/metabolismo , Transtornos do Metabolismo dos Lipídeos/diagnóstico , Transtornos do Metabolismo dos Lipídeos/epidemiologia , Transtornos do Metabolismo dos Lipídeos/genética , Cardiomiopatias/diagnóstico , Cardiomiopatias/epidemiologia , Cardiomiopatias/genética , Carnitina/deficiência , Carnitina/genética , Carnitina O-Palmitoiltransferase/deficiência , Carnitina O-Palmitoiltransferase/genética , China/epidemiologia , Síndrome Congênita de Insuficiência da Medula Óssea/diagnóstico , Síndrome Congênita de Insuficiência da Medula Óssea/epidemiologia , Síndrome Congênita de Insuficiência da Medula Óssea/genética , Feminino , Seguimentos , Humanos , Hiperamonemia/diagnóstico , Hiperamonemia/epidemiologia , Hiperamonemia/genética , Recém-Nascido , Erros Inatos do Metabolismo Lipídico/diagnóstico , Erros Inatos do Metabolismo Lipídico/epidemiologia , Erros Inatos do Metabolismo Lipídico/genética , Masculino , Erros Inatos do Metabolismo/diagnóstico , Erros Inatos do Metabolismo/epidemiologia , Erros Inatos do Metabolismo/genética , Doenças Mitocondriais/diagnóstico , Doenças Mitocondriais/epidemiologia , Doenças Mitocondriais/genética , Doenças Musculares/diagnóstico , Doenças Musculares/epidemiologia , Doenças Musculares/genética , Triagem Neonatal/métodos , Oxirredução , Espectrometria de Massas em TandemRESUMO
BACKGROUND: The relationships between lipid profiles and IBD remain elusive. AIM: To determine the association of IBD with serum lipid profiles. METHODS: A nationwide population-based study was performed using claims data from the Korean National Healthcare Insurance service. A total of 9 706 026 subjects undergoing medical check-ups in 2009 were enrolled and followed up until 2016. Individuals who developed Crohn's disease (CD) or ulcerative colitis (UC) were identified during follow-up. Adjusted hazard ratio (aHR) by age, sex, body mass index, cigarette smoking, alcohol drinking, exercise, income and underlying comorbidities was calculated to define the impact of serum lipid profiles on developing IBD. RESULTS: During a median follow-up of 7.3 years, IBD was detected in 7,058 (0.07%) individuals. Compared with the highest quartile of serum total cholesterol (TC) levels, lower TC levels were associated with higher incidence of CD (aHR: Q1, 2.52; Q2, 1.52; Q3, 1.27), but not UC. Lower serum LDL-C levels were associated with higher incidence of CD (aHR: Q1, 1.92; Q2, 1.47; Q3, 1.22), but not UC. Moreover, lower serum HDL-C levels were associated with higher incidence of CD (aHR: Q1, 2.49; Q2, 1.90; Q3, 1.43), but not UC. In contrast, lower serum triglyceride levels were associated with higher incidence of UC (aHR: Q1, 1.22; Q2, 1.19; Q3, 1.19), but not CD. CONCLUSIONS: Low serum TC, LDL-C and HDL-C levels were associated with CD. Low serum triglyceride levels were related to UC.
Assuntos
Colite Ulcerativa/epidemiologia , Doença de Crohn/epidemiologia , Transtornos do Metabolismo dos Lipídeos/epidemiologia , Lipídeos/sangue , Adulto , Colite Ulcerativa/sangue , Comorbidade , Doença de Crohn/sangue , Feminino , Seguimentos , Humanos , Incidência , Transtornos do Metabolismo dos Lipídeos/sangue , Masculino , Pessoa de Meia-Idade , República da Coreia/epidemiologiaRESUMO
OBJECTIVES: In presence of lung cancer, the additional impact of comorbidity on survival is often neglected, although comorbidities are likely to be prevalent. Our study examines the comorbidity profile and the impact of distinct conditions on survival in German lung cancer patients. MATERIAL AND METHODS: We investigated claims data from a large nationwide statutory health insurance fund of 16,202 patients initially diagnosed with lung cancer in 2009. We calculated the prevalence of comorbidities grouped according to an extension of the Elixhauser Comorbidity Index (EI). Effects of distinct comorbidities on 5-year survival were examined using multivariate Cox proportional hazards models, adjusted for sex, age and metastases at baseline. All analyses were stratified by initial lung cancer-related treatment regimen (Surgery, Chemotherapy/Radiotherapy, No treatment). Findings were visualized in the form of a comorbidome. RESULTS: Our study population was predominantly male (70.6%) with a mean age of 68.6 years, and a mean EI score of 3.94. Patients without treatment were older (74.4 years), and their comorbidity burden was higher (mean EI = 4.59). Median survival varied by subgroup (Surgery: 24.4 months, Chemotherapy/Radiotherapy: 8.8 months, No treatment: 2.0 months), and so did the comorbidity profile and the impact of distinct conditions on survival. Generally, the effect of comorbidities on survival was detrimental and the negative association was most pronounced for 'Weight Loss' and' Paralysis'. In contrast, 'Lipid Metabolism Disorders' and 'Obesity' were positively associated with survival. Noteworthily, highly prevalent conditions tended not to show any significant association. CONCLUSION: We found specific comorbidity profiles within the distinct treatment regimens. Moreover, there were negative but also some positive associations with survival, and the strength of these effects varied by stratum. Particularly the positive effects of 'Obesity" and 'Lipid Metabolism Disorders' which were robust across strata need to be further investigated to elucidate potential biomedical explanations.
Assuntos
Transtornos do Metabolismo dos Lipídeos/epidemiologia , Neoplasias Pulmonares/epidemiologia , Obesidade/epidemiologia , Doença Pulmonar Obstrutiva Crônica/epidemiologia , Idoso , Idoso de 80 Anos ou mais , Quimiorradioterapia , Comorbidade , Feminino , Alemanha/epidemiologia , Humanos , Neoplasias Pulmonares/mortalidade , Neoplasias Pulmonares/terapia , Masculino , Pessoa de Meia-Idade , Metástase Neoplásica , Análise de SobrevidaRESUMO
PURPOSE OF REVIEW: Patients with familial hypercholesterolemia, familial combined hyperlipidemia and hyperlipoprotein(a) are at high cardiovascular risk. Increasing evidence suggest that lifestyle-related risk factors such as physical inactivity, and poor diet quality could influence cardiovascular risk in these patients. Our objective is to review the evidence that supports the role of lifestyle-related factors in the prediction of cardiovascular risk in patients with inherited lipid disorders. RECENT FINDINGS: Recent studies have shown that smoking, a poor diet quality, physical inactivity, fitness levels, abdominal obesity, insulin resistance, and type 2 diabetes were associated with the presence of atherosclerosis and long-term cardiovascular outcomes in patients with familial hypercholesterolemia. Recent evidence also suggest that managing other cardiovascular risk factors such as cholesterol levels, obesity, glycemic control, blood pressure, smoking, physical inactivity, and diet quality could reduce long-term cardiovascular risk associated with hyperlipoprotein(a). Whether targeting these risk factors could ultimately decrease cardiovascular risk in these patients remains unknown. SUMMARY: Although reducing the number of atherogenic apolipoprotein-B containing particle with lipid-lowering therapy represents the cornerstone of treatment of patients with inherited lipid disorders, lifestyle-related risk factors such as physical inactivity and poor diet quality need to be targeted for the optimal management of these high-risk patients.
Assuntos
Estilo de Vida , Transtornos do Metabolismo dos Lipídeos/genética , Doenças Cardiovasculares/complicações , Humanos , Hiperlipoproteinemia Tipo II/complicações , Transtornos do Metabolismo dos Lipídeos/complicações , Transtornos do Metabolismo dos Lipídeos/epidemiologia , RiscoRESUMO
Despite their wide and global use, possible short and long-term effects of fertility treatments on children is not well-established. In this review, birth defects and perinatal complications and their relationship with assisted reproductive technology (ART), along with long-term effects of ART on cardiovascular system, metabolism, behavior, cognitive skills, and childhood cancers are discussed. Children conceived through ART are at increased risk for birth defects and perinatal complications such as preterm delivery, low birth weight and small for gestational age. Parental characteristics, underlying infertility etiology and ART procedures themselves may contribute to this. The long-term effects of ART are difficult to establish. Studies so far report that ART children have normal social, emotional, cognitive, and motor functions. Likewise, despite some minor inconsistencies in some studies, they do not seem to be at increased risk for childhood cancers. However, there are a number of studies that imply vascular system may be adversely affected by ART and its possible consequences should be further investigated with follow up studies. Large scale studies with long-term follow up periods are required to determine the effects of ART on conceived children.
Assuntos
Anormalidades Congênitas/etiologia , Retardo do Crescimento Fetal/etiologia , Infertilidade Feminina/terapia , Infertilidade Masculina/terapia , Nascimento Prematuro/etiologia , Técnicas de Reprodução Assistida/efeitos adversos , Adulto , Anormalidades Congênitas/epidemiologia , Feminino , Retardo do Crescimento Fetal/epidemiologia , Transtornos do Metabolismo de Glucose/epidemiologia , Transtornos do Metabolismo de Glucose/etiologia , Humanos , Recém-Nascido de Baixo Peso , Recém-Nascido , Recém-Nascido Pequeno para a Idade Gestacional , Infertilidade Feminina/fisiopatologia , Infertilidade Masculina/fisiopatologia , Transtornos do Metabolismo dos Lipídeos/epidemiologia , Transtornos do Metabolismo dos Lipídeos/etiologia , Masculino , Gravidez , Nascimento Prematuro/epidemiologia , Risco , Doenças Vasculares/epidemiologia , Doenças Vasculares/etiologiaRESUMO
The authors evaluated negative effects of cadmium and arsenic compounds on health of population residing near storage of extraction and processing waste of ore mining and processing enterprise. Hygienic analysis covered quality of ambient air, drinkable water and foods, evaluation of risk factors of lipid metabolism disorders. Clinical and laboratory examination involved 137 children and 99 adults in chronic multi-environmental (ambient air, water, foods) exposure to metals (cadmium and arsenic, HI 1.21-1.29), diagnosed endocrine diseases including lipid metabolism disorders (excessive nutrition and obesity, E67.8-66.0) in adults 1.4 times more, and in children in 1.7-2.2 times more than in the reference group. Direct probable statistically significant cause-effect relationship was established between lipid metabolism disorders and serum levels of cadmium and arsenic (R² = 0,36-0,95; 71,07≤ F ≤2597,94; p< 0,001). In multi-environmental exposure to cadmium and arsenic, reduced index of lipid metabolic disorders risk in adult population exceeds upper limit of low risk level (0,05) at 33 years of age, of high risk level (0,35) - at 58 years of age and very high (0,6) - at 63 years of age.
Assuntos
Arsênio/sangue , Cádmio/sangue , Exposição Ambiental , Transtornos do Metabolismo dos Lipídeos , Mineração , Adolescente , Adulto , Fatores Etários , Poluentes Atmosféricos/efeitos adversos , Criança , Exposição Ambiental/efeitos adversos , Exposição Ambiental/análise , Exposição Ambiental/prevenção & controle , Feminino , Contaminação de Alimentos/análise , Contaminação de Alimentos/prevenção & controle , Humanos , Transtornos do Metabolismo dos Lipídeos/diagnóstico , Transtornos do Metabolismo dos Lipídeos/epidemiologia , Transtornos do Metabolismo dos Lipídeos/etiologia , Transtornos do Metabolismo dos Lipídeos/prevenção & controle , Masculino , Pessoa de Meia-Idade , Medição de Risco , Fatores de Risco , Federação Russa/epidemiologia , Fatores de Tempo , Poluentes Químicos da Água/efeitos adversosRESUMO
INTRODUCTION: Atrial fibrillation (AF) is the most common form of arrhythmia in humans and is associated with substantial morbidity and mortality. Obesity and diabetes have been linked to myocardial lipotoxicity - a condition where the heart accumulates and produces toxic lipid species. We hypothesized that obesity and diabetes were involved in the pathophysiology of AF by means of promoting a lipotoxic phenotype in atrial muscle, and that AF predicts mortality in cardiac care patients. METHODS: Our study consists of two parts. The first part is a registry study based on prospective data obtained through the Register of Information and Knowledge about Swedish Heart Intensive Care Admissions (RIKS-HIA) from hospitals in western Sweden. All consecutive patients between 2006 and 2011 admitted to coronary care unit (CCU) with sinus rhythm (SR) or AF were included in the analysis. Multivariate logistic regression and Cox proportional-hazards regression were used to test whether diabetes and obesity were independent predictors of AF at admission to CCU and whether AF was associated with increased one-year mortality. In the second part we obtained atrial biopsies from 54 patients undergoing cardiac surgery and performed lipidomic analysis for a detailed qualitative and quantitative analysis of lipid species including triglycerides (TAG), ceramides (CER), phosphatidylcholine (PC), lysophosphatidylcholine (LPC), phosphatidylethanolamine (PE), sphyngomyelins (SM), free cholesterol (FC), cholesterol esters (CEs) and diacylglycerols (DAGs). RESULTS: Between 2006 and 2011, 35232 patients were admitted to CCUs in western Sweden, mostly due to ischemic heart disease, heart failure, arrhythmia, syncope and chest pain. The mean age was 66years and 58.7% were male. There was a high prevalence of obesity (20.3%) and diabetes (16.8%). Obesity (OR 1.35, 95% CI 1.17-1.56, P<0.001) and severe obesity (1.6, 95% CI 1.29-1.99, P<0.001) were independent predictors of AF but diabetes was not (OR=0.92, 95% CI=0.82-1.04). AF increased one-year mortality (HR 1.32, 95% CI 1.16-1.50, P<0.001). Lipidomic analysis revealed that atrial TAG content was substantially lower in the AF patients (P<0.05). No quantitative difference was found in the content of CER, PC, LPC, PE, SM, FC, CE and DAG, between the patients who had AF or sinus rhythm at admission to the CCU. AF patients had greater proportion of polyunsaturated DAG (P<0.05) while no difference was found in saturated DAG. CONCLUSION: Obesity but not diabetes is an independent predictor of AF and AF is associated with increased one-year mortality in this CCU population. AF is associated with quantitative and qualitative alterations in atrial lipid content but not with lipotoxicity.
Assuntos
Fibrilação Atrial/epidemiologia , Cardiomiopatias Diabéticas/epidemiologia , Hospitalização/estatística & dados numéricos , Transtornos do Metabolismo dos Lipídeos/epidemiologia , Obesidade/epidemiologia , Sistema de Registros , Distribuição por Idade , Idoso , Fibrilação Atrial/metabolismo , Causalidade , Comorbidade , Unidades de Cuidados Coronarianos/estatística & dados numéricos , Cardiomiopatias Diabéticas/metabolismo , Feminino , Humanos , Incidência , Metabolismo dos Lipídeos , Transtornos do Metabolismo dos Lipídeos/metabolismo , Masculino , Pessoa de Meia-Idade , Obesidade/metabolismo , Medição de Risco , Distribuição por Sexo , Suécia/epidemiologiaRESUMO
The importance of the metabolic disorders and their impact on patients with HIV infection requires an individualized study and continuous updating. HIV patients have the same cardiovascular risk factors as the general population. The HIV infection per se increases the cardiovascular risk, and metabolic disorders caused by some antiretroviral drugs are added risk factors. For this reason, the choice of drugs with a good metabolic profile is essential. The most common metabolic disorders of HIV infected-patients (insulin resistance, diabetes, hyperlipidemia or osteopenia), as well as other factors of cardiovascular risk, such as hypertension, should also be dealt with according to guidelines similar to the general population, as well as insisting on steps to healthier lifestyles. The aim of this document is to provide a query tool for all professionals who treat HIV-patients and who may present or display any metabolic disorders listed in this document.
Assuntos
Doenças Cardiovasculares/epidemiologia , Infecções por HIV/epidemiologia , Doenças Metabólicas/epidemiologia , Fármacos Anti-HIV/efeitos adversos , Doenças Cardiovasculares/prevenção & controle , Comorbidade , Exercício Físico , Promoção da Saúde , Estilo de Vida Saudável , Humanos , Transtornos do Metabolismo dos Lipídeos/induzido quimicamente , Transtornos do Metabolismo dos Lipídeos/epidemiologia , Doenças Metabólicas/induzido quimicamente , Doenças Metabólicas/terapia , Fatores de Risco , Disfunções Sexuais Fisiológicas/epidemiologia , Disfunções Sexuais Fisiológicas/etiologia , Abandono do Hábito de FumarRESUMO
OBJECTIVE: This consensus document is an update of metabolic disorders and cardiovascular risk (CVR) guidelines for HIV-infected patients. METHODS: This document has been approved by an expert panel of GEAM, SPNS and GESIDA after reviewing the results of efficacy and safety of clinical trials, cohort and pharmacokinetic studies published in biomedical journals (PubMed and Embase) or presented in medical scientific meetings. Recommendation strength and the evidence in which they are supported are based on the GRADE system. RESULTS: A healthy lifestyle is recommended, no smoking and at least 30min of aerobic exercise daily. In diabetic patients the same treatment as non-HIV infected patients is recommended. HIV patients with dyslipidemia should be considered as high CVR, thus its therapeutic objective is an LDL less than 100mg/dL. The antihypertensive of ACE inhibitors and ARAII families are better tolerated and have a lower risk of interactions. In HIV-patients with diabetes or metabolic syndrome and elevated transaminases with no defined etiology, the recommended is to rule out a hepatic steatosis Recommendations for action in hormone alterations are also updated. CONCLUSIONS: These new guidelines update previous recommendations regarding all those metabolic disorders involved in CVR. Hormone changes and their management and the impact of metabolic disorders on the liver are also included.
Assuntos
Doenças Cardiovasculares/epidemiologia , Infecções por HIV/epidemiologia , Doenças Metabólicas/epidemiologia , Fármacos Anti-HIV/efeitos adversos , Doenças Cardiovasculares/prevenção & controle , Comorbidade , Exercício Físico , Promoção da Saúde , Estilo de Vida Saudável , Humanos , Transtornos do Metabolismo dos Lipídeos/induzido quimicamente , Transtornos do Metabolismo dos Lipídeos/epidemiologia , Doenças Metabólicas/induzido quimicamente , Doenças Metabólicas/terapia , Fatores de Risco , Disfunções Sexuais Fisiológicas/epidemiologia , Disfunções Sexuais Fisiológicas/etiologia , Abandono do Hábito de FumarRESUMO
BACKGROUND AND PURPOSE: The study aims to compare lipid profiles among ischemic stroke patients in a predominantly Caribbean-Hispanic population in Miami and a Mestizo Hispanic population in Mexico City. METHODS: We analyzed ischemic stroke Hispanic patients with complete baseline fasting lipid profile enrolled contemporaneously in the prospective registries of two tertiary care teaching hospitals in Mexico City and Miami. Demographic characteristics, risk factors, medications, ischemic stroke subtype, and first fasting lipid profile were compared. Vascular risk factor definitions were standardized. Multiple linear regression analysis was performed to compare lipid fractions. RESULTS: A total of 324 patients from Mexico and 236 from Miami were analyzed. Mexicans were significantly younger (58 · 1 vs. 67 · 4 years), had a lower frequency of hypertension (53 · 4% vs. 79 · 7%), and lower body mass index (27 vs. 28 · 5). There was a trend toward greater prevalence of diabetes in Mexicans (31 · 5 vs. 24 · 6%, P = 0 · 07). Statin use at the time of ischemic stroke was more common in Miami Hispanics (18 · 6 vs. 9 · 4%). Mexicans had lower total cholesterol levels (169 · 9 ± 46 · 1 vs. 179 · 9 ± 48 · 4 mg/dl), lower low-density lipoprotein (92 · 3 ± 37 · 1 vs. 108 · 2 ± 40 · 8 mg/dl), and higher triglyceride levels (166 · 9 ± 123 · 9 vs. 149 · 2 ± 115 · 2 mg/dl). These differences remained significant after adjusting for age, gender, hypertension, diabetes, body mass index, smoking, ischemic stroke subtype, and statin use. CONCLUSION: We found significant differences in lipid fractions in Hispanic ischemic stroke patients, with lower total cholesterol and low-density lipoprotein, and higher triglyceride levels in Mexicans. These findings highlight the heterogeneity of dyslipidemia among the Hispanic race-ethnic group and may lead to different secondary prevention strategies.
Assuntos
Isquemia/epidemiologia , Transtornos do Metabolismo dos Lipídeos/epidemiologia , Acidente Vascular Cerebral/epidemiologia , Acidente Vascular Cerebral/metabolismo , Adulto , Idoso , Idoso de 80 Anos ou mais , Feminino , Hispânico ou Latino , Hospitais de Ensino/estatística & dados numéricos , Humanos , Isquemia/complicações , Metabolismo dos Lipídeos , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Acidente Vascular Cerebral/etiologiaRESUMO
AIMS: A high prevalence of a low glomerular filtration rate (GFR) has recently been reported in patients with diabetes without albuminuria. We aimed to clarify the clinical characteristics of such patients, including the associations between these characteristics and atherosclerosis. METHODS: We investigated the correlations between the estimated GFR (eGFR) and lipid profiles, the ankle-brachial index (ABI) and the intima-media thickness (IMT) in 450 patients with type 2 diabetes without macroalbuminuria. RESULTS: The prevalence of renal insufficiency (RI) (GFR ï¼60 mL/min/1.73 m(2)) in the patients without albuminuria was 19.1%. The ABI values of the patients with RI were significantly lower than those of the patients without RI, regardless of the presence of microalbuminuria, while there were no significant differences in IMT between the patients with and without RI. In a multivariate analysis, a low ABI was found to be significantly associated with a low eGFR, independent of age, sex, smoking, history of hypertension and/or dyslipidemia and duration of diabetes (ß=0.134, p=0.013), whereas no significant associations were observed between the ABI and the urinary albumin excretion rate (UAER). The ApoB/LDL-C ratios and levels of ApoC3 were significantly higher in the patients with RI than those observed in the patients without RI, regardless of the presence of albuminuria. CONCLUSIONS: RI without albuminuria is closely associated with atherosclerosis of the peripheral arteries in diabetic patients. Furthermore, alterations in lipid metabolism may underlie this association.
Assuntos
Albuminas/análise , Albuminúria/diagnóstico , Complicações do Diabetes/complicações , Diabetes Mellitus Tipo 2/complicações , Transtornos do Metabolismo dos Lipídeos/complicações , Doença Arterial Periférica/complicações , Insuficiência Renal/complicações , Idoso , Índice Tornozelo-Braço , Índice de Massa Corporal , Espessura Intima-Media Carotídea , Estudos Transversais , Diabetes Mellitus Tipo 2/epidemiologia , Feminino , Taxa de Filtração Glomerular , Humanos , Hipertensão/complicações , Hipertensão/fisiopatologia , Metabolismo dos Lipídeos , Transtornos do Metabolismo dos Lipídeos/epidemiologia , Masculino , Pessoa de Meia-Idade , Modelos Estatísticos , Análise Multivariada , Doença Arterial Periférica/epidemiologia , Prevalência , Insuficiência Renal/epidemiologia , FumarRESUMO
OBJECTIVE: Multimorbidity is a complex phenomenon with an almost endless number of possible disease combinations with unclear implications. One important aspect in analyzing the clustering of diseases is to distinguish between random coexistence and statistical dependency. We developed a model to account for random coexistence based on stochastic distribution. We analyzed if the number of diseases of the patients influences the occurrence rates of chronic conditions. METHODS: We analyzed claims data of 121,389 persons aged 65+ using a list of 46 chronic conditions. Expected prevalences were simulated by drawing without replacement from all observed diseases using observed overall prevalences as initial probability weights. To determine if a disease occurs more or less frequently than expected by chance we calculated observed-minus-expected deltas for each disease. We defined clinical relevance as |delta| ≥ 5.0%. 18 conditions were excluded because of a prevalence < 5.0%. RESULTS: We found that (1) two chronic conditions (e.g. hypertension) were more frequent than expected in patients with a low number of comorbidities; (2) four conditions (e.g. renal insufficiency) were more frequent in patients with many comorbidities; (3) six conditions (e.g. cancer) were less frequent with many comorbidities; and (4) 16 conditions had an average course of prevalences. CONCLUSION: A growing extent of multimorbidity goes along with a rapid growth of prevalences. This is for the largest part merely a stochastic effect. If we account for this effect we find that only few diseases deviate from the expected prevalence curves. Causes for these deviations are discussed. Our approach also has methodological implications: Naive analyses of multimorbidity might easily be affected by bias, because the prevalence of all chronic conditions necessarily increases with a growing extent of multimorbidity. We should therefore always examine and discuss the stochastic interrelations between the chronic conditions we analyze.
Assuntos
Doença Crônica/epidemiologia , Idoso , Aterosclerose/epidemiologia , Diabetes Mellitus/epidemiologia , Feminino , Humanos , Hipertensão/epidemiologia , Transtornos do Metabolismo dos Lipídeos/epidemiologia , Dor Lombar/epidemiologia , Masculino , Neoplasias/epidemiologia , Prevalência , Insuficiência Renal/epidemiologia , Doenças da Glândula Tireoide/epidemiologiaRESUMO
BACKGROUND: Patients satisfying the National Institutes of Health criteria and deemed appropriate candidates often do not undergo bariatric surgery for insurance-related reasons. Our objective was to explore the natural history of these patients compared with that of those who underwent laparoscopic Roux-en-Y gastric bypass (LRYGB). METHODS: The medical records of the patients evaluated for LRYGB from 2001 to 2007 were retrospectively reviewed. The presence of co-morbidities was assessed at the initial evaluation and within a 3-year follow-up period for patients who had undergone LRYGB and those denied surgery. The statistical analysis included chi-square tests. RESULTS: A total of 189 patients were in the denied cohort and 587 in the LRYGB cohort. The age, gender, and body mass index were similar between the 2 cohorts at the initial evaluation. The percentage of patients with a diagnosis of a co-morbidity in the denied and LRYGB cohorts at the initial evaluation was 20% and 25% with diabetes mellitus, 51% and 43% with hypertension, 20% and 22% with obstructive sleep apnea, 34% and 24% with lipid disorders, and 62% and 49% with gastroesophageal reflux disease, respectively. The body mass index at the initial evaluation and during follow-up was 47.3 and 46.8 kg/m(2) in the denied cohort (n = 165, P = .236) and 48.5 and 30.5 kg/m(2) in the LRYGB cohort (n = 544, P <.001), respectively. During the follow-up period, a greater incidence of new-onset diabetes (P <.001), hypertension (P <.001), obstructive sleep apnea (P <.001), gastroesophageal reflux disease (P <.001), and lipid disorders (P <.001) was observed in the denied cohort. CONCLUSION: Patients denied LRYGB had a greater incidence of new co-morbidities diagnosed within a short follow-up period, without a significant change in their body mass index.
Assuntos
Derivação Gástrica/economia , Seguro Saúde , Obesidade Mórbida/epidemiologia , Obesidade Mórbida/fisiopatologia , Adulto , Doenças Cardiovasculares/epidemiologia , Estudos de Coortes , Comorbidade , Efeitos Psicossociais da Doença , Diabetes Mellitus Tipo 2/epidemiologia , Feminino , Derivação Gástrica/estatística & dados numéricos , Refluxo Gastroesofágico/epidemiologia , Humanos , Hipertensão/epidemiologia , Revisão da Utilização de Seguros , Transtornos do Metabolismo dos Lipídeos/epidemiologia , Masculino , Pessoa de Meia-Idade , Obesidade Mórbida/metabolismo , Apneia Obstrutiva do Sono/epidemiologiaRESUMO
Although skin tags are associated with diabetes mellitus, insulin resistance, hypertension, obesity, atherogenic lipid profile, no data in the literature show that the presence of skin tags is associated with serum high-sensitive C-reactive protein, uric acid, free fatty acid and leptin level. The purpose of this study was to evaluate the frequency of hypertension, dyslipidemia, insulin resistance and obesity in patients with skin tags and to compare patients with skin tags and normal healthy subjects for insulin resistance, serum lipids, insulin, glucose, leptin, high-sensitive C-reactive protein, free fatty acid levels. We evaluated 113 patients with skin tags and 31 healthy subjects. The two groups were compared with respect to BMI, lipid profile, blood pressure, insulin resistance, serum lipids, insulin, glucose, leptin, high-sensitive C-reactive protein, free fatty acid and homeostatic model assessment of insulin resistance (HOMA-IR). Total 53.9 and 33.6% of patients with skin tags were overweight and obese, respectively. The frequency of hypertension 30.1%, dyslipidemia 59.3% and insulin resistance 21.2% were detected. HOMA-IR (P < 0.001) and serum glucose (P < 0.001), insulin (P = 0.002), high-sensitive C-reactive protein (P = 0.001), uric acid (P = 0.001), free fatty acid (P = 0.002), HbA1c (P < 0.001), total cholesterol (P = 0.018), LDL-cholesterol (P = 0.023), and triglyceride levels (P = 0.001) were higher in patients with skin tags than control group. Overweight and/or obesity, dyslipidemia, hypertension, insulin resistance and elevated high-sensitive C-reactive protein are seen in patients with skin tags. Skin tags may be a marker of increased risk of atherosclerosis and cardiovascular disease.
Assuntos
Metaboloma , Neoplasias Cutâneas/complicações , Neoplasias Cutâneas/patologia , Adulto , Análise Química do Sangue , Feminino , Humanos , Hipertensão/epidemiologia , Resistência à Insulina , Transtornos do Metabolismo dos Lipídeos/epidemiologia , Masculino , Pessoa de Meia-Idade , Obesidade/epidemiologiaRESUMO
BACKGROUND: Although the human adenovirus-36 (Ad-36) has been associated with obesity and related lipid disorders in the United States, this association has yet to be identified in other countries. Therefore, we tried to determine whether Ad-36 is associated with obesity or lipid disorders in Korean schoolchildren. METHOD: A total of 318 Korean schoolchildren aged 6-15 years, who participated in the Ewha Womans University Obesity Research Study, were selected for a community-based cohort study. Non-obese and obese were defined as body mass index (BMI) <85th and > or = 95th percentiles of the Korean reference BMI-for-age curves, respectively, according to International Obesity Task Force definitions. The cutoff points for lipid disorders were modified from the age-modified standards of the National Cholesterol Education Program (NCEP)-Adult Treatment Panel (ATP) III metabolic syndrome criteria. The Ad-36 antibody was measured using a serum neutralization assay. RESULTS: More obese participants than non-obese participants tested positive for the Ad-36 antibody (28.57 vs 13.56%, respectively; P = 0.0174). Within the obese group, the participants who tested positive for the Ad-36 antibody had higher levels of triglycerides (TG) and total cholesterol than those who tested negative for the Ad-36 antibody (P<0.001). However, these associations were not present in the non-obese group. The unadjusted odds ratio (OR) for Ad-36 antibody positivity was greater in obese participants than non-obese participants (OR = 2.550, 95% confidence interval (CI): 1.154-5.633). However, this OR seemed to be nonsignificant when age, sex and lipid variables were included in the analysis (OR = 1.752, 95% CI: 0.763-4.020). The unadjusted OR for the elevated TG was significantly higher in participants who were Ad-36 antibody-positive than those who were Ad-36 antibody-negative (OR = 2.511, 95% CI: 1.448-4.353). This trend remained constant even after adjustment for age, sex and obesity (OR = 2.328, 95% CI: 1.296-4.181). CONCLUSION: Ad-36 seems to be strongly associated with lipid disorders in Korean schoolchildren regardless of obesity.
Assuntos
Infecções por Adenovirus Humanos/sangue , Transtornos do Metabolismo dos Lipídeos/sangue , Lipídeos/sangue , Obesidade/sangue , Infecções por Adenovirus Humanos/epidemiologia , Infecções por Adenovirus Humanos/virologia , Adenovírus Humanos/imunologia , Adolescente , Anticorpos Antivirais/sangue , Povo Asiático , Índice de Massa Corporal , Criança , Feminino , Humanos , Coreia (Geográfico)/epidemiologia , Transtornos do Metabolismo dos Lipídeos/epidemiologia , Transtornos do Metabolismo dos Lipídeos/virologia , Masculino , Obesidade/epidemiologia , Obesidade/virologia , Razão de Chances , Fatores de Risco , EstudantesRESUMO
The main purpose of this research was to study the impact of hormonotherapy on changes of the lipid metabolism in patients with breast cancer. 451 breast cancer patients were under investigation. Depending on the treatment method, all patients were divided into four groups. The first group was composed of 117 patients who received hormonotherapy consisting of tamoxifen 20 mg/day; the second group was composed of 115 patients who received Toremifen 60 mg/day; The third group was composed of 106 patients who received Toremifen 240 mg/day; The fourth group consisted of 113 patients who received Letrozol 2,5 mg/day. To determine of lipid metabolism disorders, we estimated cholesterol fractions, triglycerides and high and low density lipoproteins both prior to the beginning of hormonotherapy, and in 3, 6, 12 months. After 12 month of hormonotherapy with Tamoxifen 20 mg/day all fractions of very low density lipoproteins were increased. Patients treated with Toremifen 240 mg/day demonstrated increase of total cholesterol and triglycerides in blood and decrease of concentration of high density lipoproteins. In the groups of patients who were treated with Toremifen 60 mg/day and Letrazol 2,5 mg/day any considerable disorders of lipid metabolism was not observed. It is concluded that hormonotherapy of the breast cancer may lead to the disorders of lipid metabolism, which may also lead to disorders of heart-vascular system.
Assuntos
Antineoplásicos Hormonais/uso terapêutico , Inibidores da Aromatase/uso terapêutico , Neoplasias da Mama/tratamento farmacológico , Neoplasias da Mama/epidemiologia , Antagonistas de Estrogênios/uso terapêutico , Transtornos do Metabolismo dos Lipídeos/epidemiologia , Nitrilas/uso terapêutico , Tamoxifeno/uso terapêutico , Toremifeno/uso terapêutico , Triazóis/uso terapêutico , LDL-Colesterol/sangue , Dislipidemias/sangue , Dislipidemias/epidemiologia , Feminino , Humanos , Letrozol , Fatores de Tempo , Triglicerídeos/metabolismoRESUMO
AIM: The retrospective analysis of prevalence, peculiarities of duration of biliary calculosis without gall bladder cholesterosis, biliary calculosis with gall-bladder cholesterosis and xanthogranulematous cholecystitis among persons who underwent cholecystectomy using clinical, instrumental and morphological data. MATERIAL AND METHODS. The data was evaluated obtained from medical cards of 4073 inpatients operated for cholelithiasis in 1999-2005. Preoperative clinical condition, body mass index, the results of abdominal ultrasonography, morphology of removed gall-bladders were evaluated. Statistical processing was made by Student's criterion and correlation analysis. RESULTS: After cholecystectomy the diagnosis of cholelithiasis was confirmed in 4020 patients (98.7%). 1177 patients had concomitant gall-bladder cholesterosis (GBC), 38 patients-- xanthogranulematous cholecystitis (XC). GBC and XC were diagnosed morphologically only in the postoperative stage. The patients were divided into three groups: cholelithiasis without GBC (32 patients), cholelithiasis with GBC (68 patients), XC (38 patients). Diseases of the gall-bladder occur more frequent in women and older patients. XC in males occurred 2 times more frequently, cholelithiasis without cholesterosis and XC ran 2 times less. The above diseases are related with disorders of metabolism and lipid transport. GB dyskinesia has different causes in each of the diseases. CONCLUSION: The analysis determined peculiarities of duration of cholelithiasis without gall-bladder cholesterosis, cholelithiasis with GBC and XC. This necessitate differential therapy.
Assuntos
Colecistectomia/métodos , Colecistite/diagnóstico , Colelitíase/diagnóstico , Transtornos do Metabolismo dos Lipídeos/diagnóstico , Xantomatose/diagnóstico , Adulto , Idoso , Colecistite/complicações , Colecistite/epidemiologia , Colelitíase/complicações , Colelitíase/epidemiologia , Diagnóstico Diferencial , Feminino , Humanos , Incidência , Transtornos do Metabolismo dos Lipídeos/complicações , Transtornos do Metabolismo dos Lipídeos/epidemiologia , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Ucrânia/epidemiologia , Xantomatose/complicações , Xantomatose/epidemiologiaRESUMO
UNLABELLED: Atherosclerosis is a disease of adult patients, however, it begins in childhood and progresses from fatty streaks to raised lesions in arteries in adolescence and young adults. Clinical manifestation of atherosclerosis in adulthood depends on the risk factors such as: lipid disorders, obesity, hypertension, smoking habits and family history of CHD. High serum homocysteine concentration is increasingly recognised as a new risk factor for atherosclerosis and other vascular diseases. Atherogenic effect of homocystein is related to cytotoxin action on the endothelial cells and their function. The aim of this study was to estimate relations between the homocysteine serum concentration and the lipid levels in children with atherosclerosis risk factors. MATERIAL AND METHODS: The study was carried out on 48 children with atherosclerosis risk factors. The control group consisted of 25 healthy childrens. Total cholesterol (TC), Triglycerides (TG), HDL-C, LDL-C were determined by enzymatic method. Concentration of homocysteine was estimated by immunoenzymatic method (ELISA). RESULTS: Obesity, lipid disorders, and hypertension were the most frequent risk factors in the investigated children. Statistically significant higher concentration of TC, LDL-C, TG and lower HDL-C were observed in children with atherosclerosis risk factors. No significant differences in homocystein concentration were observed in the investigated groups, but homocystein concentration was significantly higher in group of children with atherosclerosis risk factors. CONCLUSION: We observed that increased number of the risk factors is followed by high homocystein concentration in the serum.
Assuntos
Aterosclerose/sangue , HDL-Colesterol/sangue , LDL-Colesterol/sangue , Homocisteína/sangue , Transtornos do Metabolismo dos Lipídeos/sangue , Triglicerídeos/sangue , Adolescente , Aterosclerose/epidemiologia , Aterosclerose/prevenção & controle , Biomarcadores/sangue , Índice de Massa Corporal , Comorbidade , Feminino , Humanos , Hipercolesterolemia/epidemiologia , Hipertensão/epidemiologia , Transtornos do Metabolismo dos Lipídeos/epidemiologia , Lipoproteínas/sangue , Masculino , Obesidade/sangue , Obesidade/epidemiologia , Fatores de RiscoRESUMO
UNLABELLED: Incidentally diagnosed, clinically asymptomatic adrenal masses (incidentaloma) have become more and more common problem in everyday clinical practice. The prevalence of such tumors is 2.3% in autopsy series and 0.5-2% in computed tomography series. The aim of the study was a clinical analysis of patients with adrenal incidentaloma, hospitalized in the Department of Internal and Metabolic Diseases of the Medical University of Silesia. MATERIAL AND METHODS: 33 patients, including 25 females (75.7%) and 8 males (24.3%), were investigated. The mean age was 59.0 +/- 10.7 year (31-80) and the mean body mass index (BMI) was 29.6 +/- 5.9 kg/m2 (19.4-47). RESULTS: 16 patients (48.5%) were obese and 10 more patients (30.3%) were overweight. Hypertension was diagnosed in 25 patients (75.8%), diabetes or impaired glucose tolerance in 9 patients (27.3%) and hyperlipidemia in 20 patients (60.6%). Endocrine tests revealed: disturbed cortisol rhythm in 1 patient, uncertain result of the overnight dexamethasone suppression test in 4 patients, elevated urinary 17-hydroxycorticosteroids excretion in 7 patients, elevated urinary 17-ketosteroids excretion in 2 patients and increased urinary excretion ofvanillylmandelic acid in 2 patients. The tumor was located in the right adrenal gland in 13 patients (39.4%) and in the left adrenal gland in 16 patients (48.5%). 4 patients (12.1%) demonstrated bilateral adrenal masses. At least one of the tumor sizes was greater than 40 mm in 3 patients (9.1%). CONCLUSION: Clinically asymptomatic adrenal tumors occurred more frequently in overweight or obese women, between 51-70 years old, with lipid disorders and hypertension.